Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: pure versus non-pure Cis.
CONCLUSIONS: Pure Cis and non-pure Cis are efficiently treated by BCG therapy combined with transurethral resection and/or radical cystectomy, with relatively low rate of progression. Cis type was the only significant predictor of progression.
PMID: 31144485 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Smokers | Urology & Nephrology